EUCTR2008-004864-38-FR进行中（未招募）1 期
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C
Schering Plough Research Institute, A Division of Schering Corporation0 个研究点目标入组 99 人开始时间: 2009年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The subject must fulfill ALL the criteria listed below for entry:
- •1. Each subject must be willing and able to provide written informed consent
- •2. Subject must be =18 and =65 years of age
- •3. Subject must have a body weight =40 and =125 kg
- •4. Subject must have a documented history of HIV infection for greater than 6
- •months prior to Day 1
- •5. Subject must be on an optimized anti-retroviral treatment regimen (OTR) with
- •stable HIV disease with CD4 =200 cells/mcL and HIV-1 RNA viral load <50
- •6. Subject must have documented CHC genotype 1 infection (HCV infection
- •greater than 6 months prior to Day 1). Subjects with other or mixed
- •genotypes are not eligible. The HCV-RNA result obtained at the Screening
- •Visit must confirm genotype 1 infection and be =10,000 IU/mL
- •7. Subject must have a liver biopsy with histology consistent with CHC and no
- •other etiology. Copies of the pathology report and histology slides (suitable for
- •evaluation by the trial central pathologist) are required for the subject to be
- •included in the trial. The trial site must be able to access the pathology report
- •and histology slides prior to subject randomization. Two unstained slides are
- •preferred; however, one slide stained with hematoxylin plus eosin (H and E)
- •plus one slide stained with Masson’s trichrome will be accepted (slides should
- •be reviewed by the investigator to confirm adequacy). The central
- •pathologist’s reading will be used for analysis purposes only; randomization
- •will be performed based on the local report
- •a. If no cirrhosis is present: The liver biopsy must be within 2 years of the
- •Screening Visit
- •b. If cirrhosis is present: Any historic liver biopsy demonstrating cirrhosis
- •will be accepted regardless of the length of time since biopsy.
- •Refer to Appendix 1 for the Scoring Systems for Hepatic Fibrosis
- •c. If the timing of the liver biopsy does not meet the criteria outlined in
- •Inclusion Criteria Nos. 7a and 7b, a liver biopsy may be performed
- •between Screening and Day 1 (only if the subject’s Screening Visit
- •confirms that the subject meets the other trial inclusion criteria)
- •8. Subject with bridging fibrosis or cirrhosis must have an ultrasound within 6
- •months of the Screening Visit (or between Screening and Day 1) with no
- •findings suspicious for hepatocellular carcinoma (HCC)
- •9. Subject and subject’s heterosexual partner(s) must each agree to use
- •acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of trial medication, or longer if dictated by local regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinical Exclusion Criteria:
- •1. Prior HCV treatment other than herbal remedies must be discontinued before Day 1, except silymarin.
- •2. Coinfected with hepatitis B virus &/or signs & symptoms consistent with infection
- •3. Decompensated liver disease: ascites, bleeding varices, or hepatic encephalopathy
- •4. Anti-retroviral regimen change w/in 3 months (except zidovudine, didanosine, stavudine & HIV protease inhibitors w/out ritonavir)
- •5. Use of zidovudine, didanosine or stavudine w/in 1 month & during the trial
- •6. Significant opportunistic infections w/in 1yr
- •7. Diabetic & hypertensive subjects w/ ocular examination findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or any significant abnormality
- •8. Pre-existing psychiatric condition:
- •a. Moderate or severe depression
- •b. Depression associated with:
- •1) Hospitalization
- •2) Electroconvulsive Therapy
- •3) Prolonged work absence &/or disruption of daily functions
- •c. Suicidal or homicidal ideation/attempt
- •d. Severe psychiatric disorders
- •e. Lithium use
- •f. Antipsychotic drug use for conditions listed in 8d
- •9. Substance abuse of alcohol, intravenous drugs, inhalational (not marijuana), psychotropics, narcotics, cocaine, prescription or over-the-counter drugs or history of polysubstance abuse (=3)
- •10. Clinical diagnosis w/in the past 6 months of substance abuse
- •Clinical diagnosis requires:
- •a. Documentation w/in the past 6 months of a low risk for psychiatric exacerbation induced by interferon
- •b. Documentation of compliance by an HIV viral load <400 copies/mL for = 1yr
- •11. Receiving opiate agonist substitution therapy but not in a substitution maintenance program
- •12. Marijuana use deemed excessive or interfering w/subject's life. Subject instructed to stop use of recreational marijuana prior to the trial
- •13. Pre-existing medical condition interfering with participation:
- •a. Central nervous system trauma requiring intubation, intracranial pressure monitoring, brain meningeal or skull surgery, or resulting in seizure, coma, permanent neurologic deficits, abnormal brain imaging, cerebrospinal fluid leak, or prior brain hemorrhage and/or intracranial aneurysms
- •b. Seizure disorder unless seizure was >10 years ago, an isolated event, no anti-seizure medications prescribed, & a normal neurological examination documented w/in 6 months
- •c. Stroke or transient ischemic attack
- •d. Immunologically-mediated disease
- •e. Chronic pulmonary disease
- •f. Clinically significant cardiac abnormalities/dysfunctions including uncontrolled hypertension, or history of antianginal agents for cardiac conditions
- •g. Medical conditions requiring, or likely to require, chronic systemic administration of corticosteroids
- •h. Active clinical gout w/in 1 year
- •i. Hemoglobinopathy
- •j. Myelodysplastic syndromes
- •k. Coagulopathy
- •l. Organ transplants other than cornea & hair
- •m. Poor venous access precluding
研究者
相似试验
进行中（未招募）
不适用
A Study of Boceprevir in Patients who have HIV and Hepatitis CChronic Hepatitis CMedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: SOCClassification code 10019805Term: Hepatobiliary disordersSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2008-004864-38-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.99
进行中（未招募）
不适用
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis CEUCTR2008-004864-38-DESchering Plough Research Institute, A Division of Schering Corporation99
进行中（未招募）
不适用
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis CEUCTR2008-004864-38-NLSchering Plough Research Institute, A Division of Schering Corporation99
进行中（未招募）
1 期
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C - NDChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912EUCTR2008-004864-38-ITSchering Plough Research Institute99
进行中（未招募）
1 期
A Study of Boceprevir in Patients who have HIV and Hepatitis CChronic Hepatitis CMedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: SOCClassification code 10019805Term: Hepatobiliary disordersSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2008-004864-38-BESchering Plough Research Institute, A Division of Schering Corporation99